ReviewZoological research2026
Nanomaterial strategies for mitigating protein misfolding and neuroinflammation in neurodegenerative diseases.
Review in Zoological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A FOS/NFKB1-associated Hofbauer cell subset mediates placental niche dysregulation in early-onset fetal growth restriction.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders such as Alzheimer's disease are characterized by pathological protein misfolding, persistent neuroinflammation, and progressive synaptic deterioration. Nanoscale therapeutic platforms offer a versatile strategy for simultaneously suppressing pathogenic protein aggregation and modulating glial hyperactivation, thereby addressing the multifactorial nature of neurodegenerative pathology. Engineered AuNPs, carbon-based nanodots, and related constructs with negatively charged surfaces exhibit high affinity for amyloidogenic peptides, thereby limiting amyloid-β or tau fibrillization, while photothermal strategies using graphene or gold nanorods induce localized thermal disruption of preformed aggregates, enhancing their disassembly. In parallel, functionalized nanocarriers facilitate brain-targeted delivery of anti-inflammatory agents by leveraging receptor-mediated transcytosis or biomimetic cell membrane-camouflaging strategies, attenuating proinflammatory cytokines and promoting autophagic clearance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.